Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
| Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | ||
| Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Caprelsa | Vandetanib | Medullary Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 24, 2024